Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals CofiledCriticalTakeda Pharmaceuticals Co
Publication of ECSP18006622ApublicationCriticalpatent/ECSP18006622A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención proporciona un compuesto con una actividad moduladora alostérica positiva del receptor muscarínico colinérgico M1, que puede ser útil como un fármaco preventivo o terapéutico para enfermedad de Alzheimer, esquizofrenia, dolor, trastorno del sueño, demencia por enfermedad de Parkinson, demencia por cuerpos de Lewy, y similares. La presente invención se refiere a un compuesto representado por la fórmula (I) (descrita en el adjunto a este casillero) o una de sus sales en donde cada símbolo es como se define en la descripción adjunta.The present invention provides a compound with a positive allosteric modulatory activity of the muscarinic cholinergic M1 receptor, which may be useful as a preventive or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, body dementia Lewy, and the like. The present invention relates to a compound represented by formula (I) (described in the attachment to this box) or a salt thereof wherein each symbol is as defined in the attached description.
ECIEPI20186622A2015-06-262018-01-26
DERIVATIVES OF 2,3-DIHIDRO-4H-1,3-BENZOXAZIN-4-ONA AS MODULATORS OF MUSCARINIC M1 CHOLINERGIC RECEPTOR
ECSP18006622A
(en)